Baystreet Staff - Friday, May 1, 2026 BioVaxys Technology Corp 10:39 AM EST - BioVaxys Technology Corp : Presents further validation of the Robust Immune Response from a combination of MVP-S with checkpoint inhibitors and low-dose cyclophosphamide in ovarian cancer. BioVaxys Technology Corp shares C.BIOV are trading unchanged at $0.06. Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=6537676083736926
